United States set
Menu Shopping cart $0 Search
Manufactured by BioVendor

osteomiR™ kit

  • Regulatory status:RUO
  • Type:qPCR miRNA screening panel
  • Species:Human
Cat. No. Size Price

KT-011-OT96 Analysis of 48 samples
KT-011-OT384 Analysis of 48 samples
PubMed Product Details
Technical Data


qPCR miRNA screening panel


The osteomiR TM kit enables the simple and standardized analysis of specific circulating microRNAs in human serum and plasma, which reflect bone quality.

The kit contains 19 individual bone-related biomarkers which

  • are associated to bone microstructure and histomorphometry
  • are significantly regulated in patients with osteoporotic fractures
  • are BMD-independent risk factors for osteoporotic fracture
  • regulate bone formation and resorption via multiple pathways
  • are novel biomarkers for bone disease, which can easily be detected in serum and plasma

All-In-One kit: the osteomiR TM kit includes all reagents for the RNA extraction, cDNA synthesis, Preparation of PCR Mix, real time PCR analysis, data analysis: tailored software.



Sample Requirements

200 μL of human serum



It is intended for research use only.

Each kit comprises the following components:

  1. Serum RNA extraction kit containing all reagents, spin columns and collection tubes

  2. The RT-qPCR chemistry comprising spike-in controls, all reagents for cDNA synthesis and the miGreen PCR Mix;

  3. Primer-coated qPCR plates in 96 well or 384 well format

Research topic

Bone and cartilage metabolism


The osteomiR® test enables quantitative analysis of 19 microRNAs in human serum samples. The 19 individual bone and muscle biomarkers are key orchestrators for bone formation and regeneration, osteogenic and osteoblastic differentiation, mineral apposition, osteoporosis risk and fragility fractures. The majority of miRNA is expressed by a variety of cell types including bone cells. The osteomiR® panel can be used as a fingerprint for osteoporosis or a screening tool for bone fitness.

Summary References (8)

References to bone quality - related miRNA

  • Anastasilakis AD et al. Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis. J Clin Endocrinol Metab. 2018 Mar 1;103(3):1206-1213.
  • Feichtinger X, et al. Bone-related Circulating MicroRNAs miR-29b-3p, miR550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry. Sci. Rep. 2018 20;8(1):4867.
  • Kocijan R, Muschitz C, et al. Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures. J Clin Endocrinol Metab. 2016 Aug 23.
  • Heilmeier U, Hackl M, et al. Serum microRNAs are indicative of skeletal fractures in postmenopausal women with and without type-2 diabetes and infl uence osteogenic and adipogenic diff erentiation of adipose-tissue derived mesenchymal stem cells in vitro. J Bone Miner Res 2016 Jun 27.
  • Mäkitie RE, Hackl M, et al. Altered MicroRNA Profi le in Osteoporosis Caused by Impaired WNT Signaling. JCEM 2018 ;Mar 1.
  • Kocijan et al., Time-dependent Analysis of microRNAs and Bone Microstructure under consideration of Anti-osteoporotic Treatment. Unpublished
  • Weilner S, et al. Secreted microvesicular miR-31 inhibits osteogenic diff erentiation of mesenchymal stem cells. Aging Cell 2016; 1–11.
  • Li D, et al, Osteoclast-derived exosomal miR 214-3p inhibits osteoblastic bone formation. Nat Commun, 2016, Mar 7;7:10872.
Related Products Docs